Meeting
2015 Gastrointestinal Cancers Symposium
A phase I/II study of divided-dose docetaxel, cisplatin, and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Authors
Toshiyasu Ojima
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
Toshiyasu Ojima , Mikihito Nakamori , Masaki Nakamura , Makoto Iwahashi , Masahiro Katsuda , Keiji Hayata , Shuichi Matsumura , Hiroki Yamaue
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00915850
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 132)
DOI
10.1200/jco.2015.33.3_suppl.132
Abstract #
132
Poster Bd #
C30
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
First Author: Hironaga Satake
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Correlation between histopathological response by neoadjuvant DCF therapy and the clinical efficacy of palliative platinum-containing regimens for recurrent ESCC.
First Author: Shota Igaue
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
First Author: Jun Okui
Poster
2020 Gastrointestinal Cancers Symposium
Loss of body weight during neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil as predictive of poor survival of patients with esophageal squamous cell carcinoma.
First Author: Munehiro Ito